CAH - Cardinal Health Inc Stock Price Quote - NYSE | Morningstar

Skip to Content

Is it the right time to buy or sell?

Find out with Morningstar Investor

Is it the right time to buy or sell?

Find out with Morningstar Investor

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

Capital Allocation

INVESTOR

Cardinal's Position in the Drug Distribution Oligopoly Warrants a Narrow Moat

Equity Analyst Dylan Finley

Dylan Finley, CFA Equity Analyst

Business Strategy and Outlook

| Karen Andersen, CFA | Jun 14, 2022

Cardinal Health is a leading domestic wholesaler of branded, generic, and specialty pharmaceutical products. With over $180 billion in annual U.S. drug distribution revenue, Cardinal Health supplies over one quarter of the overall market, slightly outpaced by AmerisourceBergen and McKesson in market share. Together, the three operate as a pharmaceutical wholesale and distribution oligopoly, supplying over 90% of the U.S. market. The highly consolidated pharmaceutical wholesale market reflects the substantial scale-based cost advantages held by the largest players.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics - CAH

Cardinal Health Inc's Company Profile

Business Description

Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.

Contact

7000 Cardinal Place
Dublin, OH, 43017

T +1 614 757-5000

Lisa.Capodici@CardinalHealth.com

www.cardinalhealth.com

Sector Healthcare

Industry Medical Distribution

Most Recent Earnings Mar 31, 2022

Fiscal Year End Jun 30, 2022

Stock Type Slow Growth

Employees 47,300

Cardinal Health Inc's Related News

Sustainability Matters

What Investors Should Know About the $26 Billion Opioid Settlement

We review potential impact on valuation for the four companies involved.

15 Top-Quality Stocks

These names were recently added to the Morningstar Wide Moat Focus Index.

Susan Dziubinski

Stock Strategist Industry Reports

What Opioid Litigation Means for Healthcare Stocks

It continues to inflict pain on drug manufacturers and distributors.

10 Cheap Wide-Moat Stocks

We review the changes to the Morningstar Wide Moat Focus Index during the latest reconstitution and reveal the least-expensive names.

Susan Dziubinski

4 New Ideas From the Wide-Moat Focus Index

Plus, the 10 cheapest names in the index today.

Susan Dziubinski

Investing Specialists

Morningstar Runs the Numbers

We take a numerical look through this week's Morningstar research. Plus, our most popular articles and videos for the week ended April 12.

Morningstar.com

Stock Strategist Industry Reports

Lowering Our Pharma Distributor Moat Ratings and Valuations

All three companies still trade at 4 stars, however.

3 Ways to Reduce Risk in a Portfolio

Here are some defensive investments to consider in this volatile market.

Susan Dziubinski

Stock Strategist

Cardinal's a Critical Link in the Pharma Supply Chain

Its core operations will be needed no matter how market dynamics shift.

Stock Strategist

McKesson Is Deeply Discounted

The pharma distributor has a solid foundation and a bright outlook, in our opinion.

28 Undervalued Stocks

Though the market is slightly overvalued, our analysts are finding pockets of opportunity.

Susan Dziubinski

Quarter-End Insights

Healthcare: Valuations Improve as Concerns Over Drug Pricing Pressures Begin to Abate

Innovation, clearing regulatory picture, corporate restructurings, and capital redeployment should continue for healthcare stocks in the fourth quarter.

10 Cheap, High-Quality Stocks with Growing Yields

These 10 undervalued Morningstar US Dividend Growth Index constituents are cash-rich businesses with sustainable and growing payouts.

10 Cheap Companies That Share Profits With Investors

The Morningstar US Dividend and Buyback Index focuses on companies that are shareholder-friendly capital allocators.

10 Newest Stocks in the Wide-Moat Focus Index

The Morningstar Wide Moat Focus Index made room for some undervalued consumer defensive stocks in June.

Stock Strategist Industry Reports

How Blockchain Affects Our Coverage

We believe companies with moats from switching costs and intangible assets are less vulnerable.

Stock Analyst Update

Cardinal Is Significantly Undervalued

Disastrous quarter aside, the wide-moat firm remains in a strong long-term position within the U.S. pharmaceutical market.

Stock Analyst Update

4 Wide-Moat Buys Amid Amazon-JPM-Berkshire Announcement

Investors are underappreciating the moaty nature of the healthcare supply chain and the formidable competitive advantages that have insulated these firms.

Stock Strategist Industry Reports

Selling Drugs Is Harder Than It Looks

New competition may seem inevitable, but moats in the pharma supply chain exist for a reason.

10 Cheap Stocks With Growing Dividends

The Morningstar US Dividend Growth Index homes in on cash-rich businesses with sustainable and growing yields.

Transparency is our policy. Learn how it impacts everything we do.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.